198 related articles for article (PubMed ID: 37204512)
1. Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database.
Oura M; Oguro F; Agatsuma N; Imamaki H; Nishikawa Y
Cancer Chemother Pharmacol; 2023 Jul; 92(1):7-14. PubMed ID: 37204512
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
[TBL] [Abstract][Full Text] [Related]
3. Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database.
Mitsuboshi S; Niimura T; Yoshino M; Sakamoto Y; Zamami Y; Ishizawa K
Int J Clin Pharm; 2022 Feb; 44(1):260-263. PubMed ID: 34482500
[TBL] [Abstract][Full Text] [Related]
4. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
5. Oral fluoropyrimidines: a closer look at their toxicities.
Macdonald JS
Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
[TBL] [Abstract][Full Text] [Related]
6. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Kadoyama K; Miki I; Tamura T; Brown JB; Sakaeda T; Okuno Y
Int J Med Sci; 2012; 9(1):33-9. PubMed ID: 22211087
[TBL] [Abstract][Full Text] [Related]
7. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
[TBL] [Abstract][Full Text] [Related]
8. Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Nies AT; Magdy T; Schwab M; Zanger UM
Adv Cancer Res; 2015; 125():217-43. PubMed ID: 25640272
[TBL] [Abstract][Full Text] [Related]
9. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines.
Diasio RB
Drugs; 1999; 58 Suppl 3():119-26. PubMed ID: 10711850
[TBL] [Abstract][Full Text] [Related]
10. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
McCleary NJ; Meyerhardt JA; Green E; Yothers G; de Gramont A; Van Cutsem E; O'Connell M; Twelves CJ; Saltz LB; Haller DG; Sargent DJ
J Clin Oncol; 2013 Jul; 31(20):2600-6. PubMed ID: 23733765
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Acute Kidney Injury Associated With Anticancer Drugs Used in Gastric Cancer in the Japanese Adverse Drug Event Report Database.
Uchida M; Kondo Y; Suzuki S; Hosohata K
Ann Pharmacother; 2019 Dec; 53(12):1200-1206. PubMed ID: 31347378
[No Abstract] [Full Text] [Related]
12. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
13. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
14. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
15. Novel oral chemotherapy agents.
Royce ME; Hoff PM; Pazdur R
Curr Oncol Rep; 2000 Jan; 2(1):31-7. PubMed ID: 11122822
[TBL] [Abstract][Full Text] [Related]
16. A Case of Capecitabine-induced Hyperammonemia in a Patient with Colon Cancer.
Fang W; Fu Y; Wei J
Curr Drug Saf; 2018; 13(1):55-58. PubMed ID: 28782476
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Nakayama T; Noguchi S
Oncologist; 2010; 15(1):26-36. PubMed ID: 20080863
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Adverse Drug Reaction Risk in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Chisaki Y; Aoji S; Yano Y
Biol Pharm Bull; 2017; 40(6):824-829. PubMed ID: 28566626
[TBL] [Abstract][Full Text] [Related]
20. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.
Mitani S; Kadowaki S; Komori A; Sugiyama K; Narita Y; Taniguchi H; Ura T; Ando M; Sato Y; Yamaura H; Inaba Y; Ishihara M; Tanaka T; Tajika M; Muro K
Medicine (Baltimore); 2017 Jun; 96(22):e6874. PubMed ID: 28562536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
